Lead Discovery Strategies for Identification of Chlamydia pneumoniae Inhibitors.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27916800)

Published in Microorganisms on November 28, 2016

Authors

Leena Hanski1, Pia Vuorela2

Author Affiliations

1: Pharmaceutical Biology, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland. leena.hanski@helsinki.fi.
2: Pharmaceutical Biology, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki FI-00014, Finland. pia.vuorela@helsinki.fi.

Articles cited by this

A new Chlamydia psittaci strain, TWAR, isolated in acute respiratory tract infections. N Engl J Med (1986) 8.03

An epidemic of mild pneumonia due to an unusual strain of Chlamydia psittaci. J Infect Dis (1985) 2.60

Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod (2016) 2.47

Chlamydia pneumoniae infection in circulating human monocytes is refractory to antibiotic treatment. Circulation (2001) 2.36

Distribution and biological activities of the flavonoid luteolin. Mini Rev Med Chem (2009) 2.07

Activation of Raf/MEK/ERK/cPLA2 signaling pathway is essential for chlamydial acquisition of host glycerophospholipids. J Biol Chem (2003) 1.97

Luteolin, a flavonoid with potential for cancer prevention and therapy. Curr Cancer Drug Targets (2008) 1.95

Chlamydia inhibit host cell apoptosis by degradation of proapoptotic BH3-only proteins. J Exp Med (2004) 1.89

Chlamydia pneumoniae and chlamydial heat shock protein 60 stimulate proliferation of human vascular smooth muscle cells via toll-like receptor 4 and p44/p42 mitogen-activated protein kinase activation. Circ Res (2001) 1.83

Natural products in the process of finding new drug candidates. Curr Med Chem (2004) 1.76

Microbiologic efficacy of azithromycin and susceptibilities to azithromycin of isolates of Chlamydia pneumoniae from adults and children with community-acquired pneumonia. Antimicrob Agents Chemother (1998) 1.60

Multi-targeting by monotherapeutic antibacterials. Nat Rev Drug Discov (2007) 1.60

Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ Res (2003) 1.59

The Chlamydia trachomatis parasitophorous vacuolar membrane is not passively permeable to low-molecular-weight compounds. Infect Immun (1997) 1.52

Identification of MEK- and phosphoinositide 3-kinase-dependent signalling as essential events during Chlamydia pneumoniae invasion of HEp2 cells. Cell Microbiol (2002) 1.50

Expression and translocation of chlamydial protease during acute and persistent infection of the epithelial HEp-2 cells with Chlamydophila (Chlamydia) pneumoniae. Cell Microbiol (2003) 1.25

Protection against CD95-induced apoptosis by chlamydial infection at a mitochondrial step. Infect Immun (2004) 1.18

Luteolin inhibits vascular endothelial growth factor-induced angiogenesis; inhibition of endothelial cell survival and proliferation by targeting phosphatidylinositol 3'-kinase activity. Cancer Res (2004) 1.15

Cleavage of the NF-κB family protein p65/RelA by the chlamydial protease-like activity factor (CPAF) impairs proinflammatory signaling in cells infected with Chlamydiae. J Biol Chem (2010) 1.13

The Chlamydia pneumoniae invasin protein Pmp21 recruits the EGF receptor for host cell entry. PLoS Pathog (2013) 1.06

The 2012 Garrod lecture: discovery of antibacterial drugs in the 21st century. J Antimicrob Chemother (2012) 1.04

Silencing or permanent activation: host-cell responses in models of persistent Chlamydia pneumoniae infection. Cell Microbiol (2005) 1.03

Targeting of a chlamydial protease impedes intracellular bacterial growth. PLoS Pathog (2011) 0.98

A systemic network for Chlamydia pneumoniae entry into human cells. J Bacteriol (2010) 0.93

Effect of prolonged treatment with azithromycin, clarithromycin, or levofloxacin on Chlamydia pneumoniae in a continuous-infection Model. Antimicrob Agents Chemother (2002) 0.92

Treatment of Chlamydial infections: 2014 update. Expert Opin Pharmacother (2015) 0.92

Inhibitory effect of dietary phenolic compounds on Chlamydia pneumoniae in cell cultures. Biochem Pharmacol (2006) 0.91

Ultrastructural study of Chlamydia pneumoniae in a continuous-infection model. J Clin Microbiol (2001) 0.90

Differential transcriptional responses between the interferon-gamma-induction and iron-limitation models of persistence for Chlamydia pneumoniae. J Microbiol Immunol Infect (2009) 0.90

The transcript profile of persistent Chlamydophila (Chlamydia) pneumoniae in vitro depends on the means by which persistence is induced. FEMS Microbiol Lett (2008) 0.89

Activity of cathelicidin peptides against Chlamydia spp. Antimicrob Agents Chemother (2005) 0.89

Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion. Nutrients (2012) 0.88

Chlamydia pneumoniae infection in atherosclerotic lesion development through oxidative stress: a brief overview. Int J Mol Sci (2013) 0.88

Luteolin inhibits lysophosphatidylcholine-induced apoptosis in endothelial cells by a calcium/mitocondrion/caspases-dependent pathway. Planta Med (2009) 0.86

Proteomic analysis of Chlamydia pneumoniae-infected HL cells reveals extensive degradation of cytoskeletal proteins. FEMS Immunol Med Microbiol (2008) 0.86

The flavonoid luteolin increases the resistance of normal, but not malignant keratinocytes, against UVB-induced apoptosis. J Invest Dermatol (2010) 0.86

Effects of simple aromatic compounds and flavonoids on Ca2+ fluxes in rat pituitary GH(4)C(1) cells. Eur J Pharmacol (2001) 0.85

Free intracellular Ca2+ regulates bacterial lipopolysaccharide induction of iNOS in human macrophages. Immunobiology (2008) 0.85

In vivo treatment of acute Chlamydia pneumoniae infection with the flavonoids quercetin and luteolin and an alkyl gallate, octyl gallate, in a mouse model. Biochem Pharmacol (2005) 0.84

Effective macrophage redox defense against Chlamydia pneumoniae depends on L-type Ca2+ channel activation. Med Microbiol Immunol (2002) 0.83

Chlamydia pneumoniae infection of alveolar macrophages: a model. J Infect Dis (2003) 0.83

Differential effects of quercetin, a natural polyphenolic flavonoid, on L-type calcium current in pituitary tumor (GH3) cells and neuronal NG108-15 cells. J Cell Physiol (2003) 0.83

Corn mint (Mentha arvensis) extract diminishes acute Chlamydia pneumoniae infection in vitro and in vivo. J Agric Food Chem (2011) 0.82

Inhibitory activity of the isoflavone biochanin A on intracellular bacteria of genus Chlamydia and initial development of a buccal formulation. PLoS One (2014) 0.82

Chlamydophila pneumoniae induces ICAM-1 expression in human aortic endothelial cells via protein kinase C-dependent activation of nuclear factor-kappaB. Circ Res (2003) 0.82

Similarity based virtual screening: a tool for targeted library design. J Med Chem (2006) 0.82

Chlamydophila pneumoniae triggers release of CCL20 and vascular endothelial growth factor from human bronchial epithelial cells through enhanced intracellular oxidative stress and MAPK activation. J Clin Immunol (2009) 0.82

Differences in cell activation by Chlamydophila pneumoniae and Chlamydia trachomatis infection in human endothelial cells. Infect Immun (2004) 0.82

Mechanisms of apoptosis inhibition in Chlamydia pneumoniae-infected neutrophils. Int J Med Microbiol (2015) 0.81

Chlamydia (Chlamydophila) pneumoniae-induced cell death in human coronary artery endothelial cells is caspase-independent and accompanied by subcellular translocations of Bax and apoptosis-inducing factor. FEMS Immunol Med Microbiol (2006) 0.80

Chlamydial Antibiotic Resistance and Treatment Failure in Veterinary and Human Medicine. Curr Clin Microbiol Rep (2016) 0.80

Chlamydophila pneumoniae induces p44/p42 mitogen-activated protein kinase activation in human fibroblasts through Toll-like receptor 4. J Med Microbiol (2004) 0.80

Anticancer activity of small amphipathic β²,²-amino acid derivatives. Eur J Med Chem (2012) 0.80

Recent advances in technologies for developing drugs against Chlamydia pneumoniae. Expert Opin Drug Discov (2014) 0.80

Dibenzocyclooctadiene lignans from Schisandra spp. selectively inhibit the growth of the intracellular bacteria Chlamydia pneumoniae and Chlamydia trachomatis. J Antibiot (Tokyo) (2015) 0.80

Update on the combination effect of macrolide antibiotics in community-acquired pneumonia. Respir Investig (2015) 0.79

Chlamydia pneumoniae modulates human monocyte-derived dendritic cells functions driving the induction of a Type 1/Type 17 inflammatory response. Microbes Infect (2012) 0.78

Design and synthesis of 2-arylbenzimidazoles and evaluation of their inhibitory effect against Chlamydia pneumoniae. J Med Chem (2010) 0.78

Proliferative stimulation of the vascular Endothelin-1 axis in vitro and ex vivo by infection with Chlamydia pneumoniae. Thromb Haemost (2009) 0.77

Red wine, resveratrol, Chlamydia pneumoniae and the French connection. Atherosclerosis (2003) 0.77

MAPK-PPARα/γ signal transduction pathways are involved in Chlamydia pneumoniae-induced macrophage-derived foam cell formation. Microb Pathog (2014) 0.77

The Lignan-containing Extract of Schisandra chinensis Berries Inhibits the Growth of Chlamydia pneumonia. Nat Prod Commun (2015) 0.76

Polymethoxyflavones activate Ca2+-dependent apoptotic targets in adipocytes. J Agric Food Chem (2009) 0.76

Conformation study of 2-arylbenzimidazoles as inhibitors of Chlamydia pneumoniae growth. Bioorg Med Chem Lett (2012) 0.76

Amphipathic β2,2-Amino Acid Derivatives Suppress Infectivity and Disrupt the Intracellular Replication Cycle of Chlamydia pneumoniae. PLoS One (2016) 0.76